In this AMP 2023 session, Dr. Klaus Metzeler describes the current technology landscape and prognostic relevance of minimal residual disease (MRD) detection and demonstrates his experience using NGS-based MRD detection in acute myeloid leukaemia (AML), including OGT’s NGS-based SureSeq™ Myeloid MRD Panel.
Data presented by Dr. Metzeler demonstrates the high coverage uniformity of the SureSeq™ Myeloid MRD Panel and the 100% concordance rate he found between OGT’s panel and a locally-developed NGS-based panel. Dr. Metzeler’s results highlight the breadth of clinically relevant variants, including FLT3-ITD mutations, being confidently detected and the potential application of the SureSeq™ Myeloid MRD Panel as a tool for further investigation of MRD in AML samples.
Dr. Klaus H. Metzeler, MD
Professor of Translational Haematology, Dept. of Haematology, Cell Therapy, Haemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany
This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.
SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures.